Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Heska Corporation (Amendment)

$HSKA
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Get the next $HSKA alert in real time by email
SC 13G/A 1 hska13g3.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No.: 3 Name of Issuer: Heska Corp Title of Class of Securities: Common CUSIP Number: 42805E306 December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 42805E306 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Capital Management LLC - IRS # 46-5220958 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization Evanston, IL 5. Sole Voting Power: 896,854 6. Shared Voting Power: 0 7. Sole Dispositive Power: 896,854 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 896,854 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 8.3% 12. Type of Reporting Person: IA -2- CUSIP Number: 42805E306 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Partners LP - IRS # 46-5301261 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 896,854 6. Shared Voting Power: 0 7. Sole Dispositive Power: 896,854 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 896,854 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 8.3% 12. Type of Reporting Person: PN -3- CUSIP Number: 42805E306 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Russell Mollen 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 896,854 6. Shared Voting Power: 0 7. Sole Dispositive Power: 896,854 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 896,854 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 8.3% 12. Type of Reporting Person: HC -4- Item 1(a) Name of Issuer: Heska Corp (b) Address of Issuer's Principal Executive Offices: 3760 ROCKY MOUNTAIN AVENUE LOVELAND CO 80538 Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: (a) Name of Person Filing Nine Ten Capital Management LLC (b) Address of the Principal Office or, if none, residence 1603 Orrington Ave, Ste 1650 Evanston, IL 60201 (c) Citizenship United States (d) Title of Class of Securities: Common (e) CUSIP Number: 42805E306 Item 3. This statement is filed pursuant to Rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: / / Broker or Dealer registered under Section 15 of the Act. /x/ Investment Adviser in accordance with Section 240.13d-1 (b)(1)(ii)(E) Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned 896,854 ----------------- (b) Percent of class 8.3% -----
(c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 896,854 ----------- (ii) Shared power to vote or to direct the vote 0 ----------- (iii) Sole power to dispose or to direct the 896,854 disposition of ----------- (iv) Shared power to dispose or to direct the 0 disposition of -----------
Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following //. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A -5- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of the Group. N/A Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: Michelle Katauskas _____________________________ ______2-10-2023___________ Title: CCO/COO Date
Get the next $HSKA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSKA

DatePrice TargetRatingAnalyst
1/6/2023$58.00Equal-Weight → Underweight
Morgan Stanley
3/1/2022$190.00 → $161.00Equal-Weight
Morgan Stanley
2/23/2022$300.00 → $250.00Overweight
JP Morgan
1/6/2022$210.00Overweight
Piper Sandler
11/18/2021$190.00Equal-Weight
Morgan Stanley
8/4/2021$240.00 → $305.00Overweight
Piper Sandler
7/12/2021$280.00Neutral → Buy
Guggenheim
More analyst ratings

$HSKA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

    Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

    NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

    $DRI
    $EXPI
    $HSKA
    $PRVA
    Restaurants
    Consumer Discretionary
    Real Estate
    Finance

  • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

    Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSKA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSKA
 SEC Filings

See more

$HSKA
 Leadership Updates

Live Leadership Updates

See more

  • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

    LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
 Financials

Live finance-specific insights

See more

  • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

    Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

    LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

  • Heska Corporation Completes Acquisition of LightDeck Diagnostics

    LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

$HSKA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more